We have located links that may give you full text access.
Innovate therapeutic targets for autoimmune diseases: insights from proteome-wide mendelian randomization and Bayesian colocalization.
Autoimmunity 2024 December
BACKGROUND: Despite growing knowledge regarding the pathogenesis of autoimmune diseases (ADs) onset, the current treatment remains unsatisfactory. This study aimed to identify innovative therapeutic targets for ADs through various analytical approaches.
RESEARCH DESIGN AND METHODS: Utilizing Mendelian randomization, Bayesian co-localization, phenotype scanning, and protein-protein interaction network, we explored potential therapeutic targets for 14 ADs and externally validated our preliminary findings.
RESULTS: This study identified 12 circulating proteins as potential therapeutic targets for six ADs. Specifically, IL12B was judged to be a risk factor for ankylosing spondylitis ( p = 1.61E - 07). TYMP ( p = 6.28E - 06) was identified as a protective factor for ulcerative colitis. For Crohn's disease, ERAP2 ( p = 4.47E - 14), HP ( p = 2.08E - 05), and RSPO3 ( p = 6.52E - 07), were identified as facilitators, whereas FLRT3 ( p = 3.42E - 07) had a protective effect. In rheumatoid arthritis, SWAP70 ( p = 3.26E - 10), SIGLEC6 ( p = 2.47E - 05), ISG15 ( p = 3.69E - 05), and FCRL3 ( p = 1.10E - 10) were identified as risk factors. B4GALT1 ( p = 6.59E - 05) was associated with a lower risk of Type 1 diabetes (T1D). Interestingly, CTSH was identified as a protective factor for narcolepsy ( p = 1.58E - 09) but a risk factor for T1D ( p = 7.36E - 11), respectively. External validation supported the associations of eight of these proteins with three ADs.
CONCLUSIONS: Our integrated study identified 12 potential therapeutic targets for ADs and provided novel insights into future drug development for ADs.
RESEARCH DESIGN AND METHODS: Utilizing Mendelian randomization, Bayesian co-localization, phenotype scanning, and protein-protein interaction network, we explored potential therapeutic targets for 14 ADs and externally validated our preliminary findings.
RESULTS: This study identified 12 circulating proteins as potential therapeutic targets for six ADs. Specifically, IL12B was judged to be a risk factor for ankylosing spondylitis ( p = 1.61E - 07). TYMP ( p = 6.28E - 06) was identified as a protective factor for ulcerative colitis. For Crohn's disease, ERAP2 ( p = 4.47E - 14), HP ( p = 2.08E - 05), and RSPO3 ( p = 6.52E - 07), were identified as facilitators, whereas FLRT3 ( p = 3.42E - 07) had a protective effect. In rheumatoid arthritis, SWAP70 ( p = 3.26E - 10), SIGLEC6 ( p = 2.47E - 05), ISG15 ( p = 3.69E - 05), and FCRL3 ( p = 1.10E - 10) were identified as risk factors. B4GALT1 ( p = 6.59E - 05) was associated with a lower risk of Type 1 diabetes (T1D). Interestingly, CTSH was identified as a protective factor for narcolepsy ( p = 1.58E - 09) but a risk factor for T1D ( p = 7.36E - 11), respectively. External validation supported the associations of eight of these proteins with three ADs.
CONCLUSIONS: Our integrated study identified 12 potential therapeutic targets for ADs and provided novel insights into future drug development for ADs.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app